IgE-Mediated Hypersensitivity
3
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Sharp Therapeuticsertapenem
Candid TherapeuticsCizutamig
Clinical Trials (2)
Total enrollment: 50 patients across 2 trials
Safety of Ertapenem in Beta-lactam Allergic Patients.
Start: Jan 2011Est. completion: Dec 201130 patients
Phase 4Unknown
A Phase 1 Study of Cizutamig in IgE Mediated Diseases
Start: Apr 2026Est. completion: Dec 202620 patients
Phase 1Not Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.